2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 243-245
Technology and Procedures, Gene Editing, Treatment Considerations, Drug Development, Biological Processes, Hematopoiesis, Molecular Biology, Diseases, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Metabolic Disorders, Iron Overload, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric
PAPER

10 The saga complex regulates γ-globin production

Claire Drysdale, BSc, Greggory Myers, PhD2, Ginette Balbin-Cuesta, MD, PhD3, Lei Yu, PhD4, Zesen Lin, PhD5, Carea Mullin, PhD, BS6, Edgar Cruz7, Beth McGee8, Ann Friedman, MS9, Xiaofang Liu, PhD10, Sharon Singh, MD11, Jennifer Marie Jones, MD12, James Engel, PhD13, Craig Johnson14, Michael Triebwasser, MD, PhD15, Rami Khoriaty, MD16
1 University of Michigan, Ann Arbor, Michigan, United States, University of Michigan, Ann Arbor, Michigan, United States
2 University of Michigan, Ann Arbor, Michigan, United States
3 University of Michigan, Ann Arbor, Michigan, United States, University of Michigan, Ann Arbor, Michigan, United States
4 University of Michigan, Ann Arbor, Michigan, United States
5 University of Michigan, Ann Arbor, Michigan, United States
6 University of Michigan, Ann Arbor, Michigan, United States
7 University of Michigan, Ann Arbor, Michigan, United States
8 University of Michigan, Ann Arbor, Michigan, United States
9 University of Michigan, Ann Arbor, Michigan, United States
10 University of Michigan, Ann Arbor, Michigan, United States
11 University of Michigan, Ann Arbor, Michigan, United States, University of Michigan, Ann Arbor, Michigan, United States
12 University of Michigan, Ann Arbor, Michigan, United States, University of Michigan, Ann Arbor, Michigan, United States
13 University of Michigan, Ann Arbor, Michigan, United States, University of Michigan, Ann Arbor, Michigan, United States
14 University of Michigan, Ann Arbor, Michigan, United States
15 University of Michigan, Ann Arbor, Michigan, United States
16 University of Michigan, Ann Arbor, Michigan, United States, University of Michigan, Ann Arbor, Michigan, United States, University of Michigan, Ann Arbor, Michigan, United States, University of Michigan, Ann Arbor, Michigan, United States

β-hemoglobinopathies, including sickle cell disease (SCD) and β-thalassemia, are the most common monogenic disorders worldwide and cause substantial morbidity and shortened life expectancy. Despite recent advances, treatment options remain limited. Reactivation of γ-globin, the fetal β-like globin chain, markedly ameliorates the disease severity. Here, we identify a previously unrecognized role for the Spt-Ada2-GCN5 acetyltransferase (SAGA) complex in regulating γ-globin expression.

SAGA is a transcriptional coactivator complex composed of distinct functional modules, including a histone acetyltransferase (HAT) module and a histone deubiquitinase (DUB) module. Disruption of the DUB module by deletion of USP22 did not increase the proportion of γ-globin-expressing cells (F-cells) in HUDEP-2 cells. In contrast, disruption of the SAGA HAT module through TADA2B deletion significantly increased F-cell frequency. TADA2B deletion robustly increased F-cell frequency (up to 80%) and fetal hemoglobin (HbF) levels (up to 35%) in primary human erythroid cells derived from multiple healthy donors, validating our findings in HUDEP-2 cells. TADA2B loss also increased HBG1/2 pre-mRNA and mRNA transcripts while reciprocally reducing HBB pre-mRNA and mRNA expression, indicating that TADA2B regulates γ-globin expression at the transcriptional level. Importantly, TADA2B deletion did not impair erythroid maturation or confer an obvious fitness disadvantage.

TADA2B is required for the activity of the histone acetyltransferases KAT2A and KAT2B, which are incorporated into SAGA in a mutually exclusive manner and mediate H3K9 acetylation at active promoters. Re-expression of wild-type TADA2B, but not a mutant TADA2B deficient in KAT2A/B-binding, restored F-cell frequencies to baseline in TADA2B-null cells, indicating that TADA2B regulates γ-globin through its interaction with KAT2A/B. Consistent with functional redundancy of these paralogs, combined, but not individual, deletion of KAT2A and KAT2B significantly increased the proportion of F-cells. Similarly, pharmacologic degradation of KAT2A/B using the proteolysis-targeting chimera (PROTAC) GSK-699 dose-dependently increased F-cell formation, HBG1/2 transcript levels, and HbF expression without impairing erythroid maturation. SAGA and the related Ada2a-containing (ATAC) complex share a nearly identical HAT module, differing only in that SAGA incorporates TADA2B, whereas ATAC incorporates TADA2A. Deletion of the SAGA-specific subunit TADA2B, but not the ATAC-specific paralog TADA2A, induced F-cell production, demonstrating that KAT2A/B regulate γ-globin through SAGA rather than ATAC. Consistent with this conclusion, GSK-699 treatment did not further increase F-cell frequency in TADA2B-null cells.

To elucidate the mechanism by which SAGA regulates γ-globin expression, we profiled genome-wide TADA2B occupancy in HUDEP-2 cells using Cleavage Under Targets and Release Using Nuclease (CUT&RUN). TADA2B was absent from the HBG1/2 promoters, indicating that SAGA regulates γ-globin indirectly. In contrast, TADA2B was enriched at the HBB promoter. Because deletions of the HBB promoter have been shown to induce γ-globin expression by relieving competition for the locus control region, we tested whether that SAGA contributes to HBG1/2 silencing by directly activating HBB transcription. However, TADA2B deletion further increased γ-globin expression in clonal cells harboring an HBB promoter deletion, indicating that reduced HBB expression alone cannot fully account for the effects of SAGA disruption.

To identify additional mechanisms, we compared the transcriptomes of TADA2B-deleted and control primary human erythroid cells by RNA-seq and integrated these data with the CUT&RUN results. This analysis nominated the γ-globin repressors BCL11A and ZBTB7A as direct SAGA target genes. Functional validation demonstrated that ZBTB7A overexpression had no detectable effect on γ-globin induction following TADA2B deletion, whereas BCL11A overexpression partially, but not completely, attenuated the phenotype. Together, these findings indicate that SAGA maintains γ-globin silencing through both BCL11A-dependent and BCL11A-independent mechanisms.

Finally, GSK-699 treatment of primary erythroid cells from individuals with SCD increased HbF from 5% to 35% and markedly reduced hypoxia-induced sickling ex vivo. Collectively, these findings support KAT2A/B disruption as a promising therapeutic strategy for β-hemoglobinopathies.

Claire Drysdale, BSc: No relevant conflicts of interest to declare.